<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Benedict K</submitter><funding>Intramural CDC HHS</funding><pagination>myaf049</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12281149</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>63(6)</volume><pubmed_abstract>We conservatively estimated the annual US fungal disease-related economic burden as $19.4 billion, including direct medical costs ($13.4 billion) of hospitalizations (n = 133 555) and outpatient visits (n = 13.4 million), $1.7 billion from absenteeism, and $4.3 billion from deaths (n = 7288). These findings underscore the need for fungal disease surveillance, treatment, and prevention efforts.</pubmed_abstract><journal>Medical mycology</journal><pubmed_title>Economic burden of fungal diseases in the United States.</pubmed_title><pmcid>PMC12281149</pmcid><funding_grant_id>CC999999</funding_grant_id><pubmed_authors>Gold JAW</pubmed_authors><pubmed_authors>Benedict K</pubmed_authors><pubmed_authors>Chiller T</pubmed_authors><pubmed_authors>Lyman M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Economic burden of fungal diseases in the United States.</name><description>We conservatively estimated the annual US fungal disease-related economic burden as $19.4 billion, including direct medical costs ($13.4 billion) of hospitalizations (n = 133 555) and outpatient visits (n = 13.4 million), $1.7 billion from absenteeism, and $4.3 billion from deaths (n = 7288). These findings underscore the need for fungal disease surveillance, treatment, and prevention efforts.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jun</publication><modification>2026-03-27T16:53:46.729Z</modification><creation>2025-08-28T03:08:56.057Z</creation></dates><accession>S-EPMC12281149</accession><cross_references><pubmed>40455586</pubmed><doi>10.1093/mmy/myaf049</doi></cross_references></HashMap>